Vicente V. Valero
Experienced in Malnutrition

Dr. Vicente V. Valero

Thoracic Surgery | General Surgery
Crescent City Physicians Inc
2820 Canal St, 
New Orleans, LA 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Experienced in Malnutrition
Crescent City Physicians Inc
2820 Canal St, 
New Orleans, LA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Vicente Valero is a Thoracic Surgeon and a General Surgeon in New Orleans, Louisiana. Dr. Valero is rated as an Experienced provider by MediFind in the treatment of Malnutrition. His top areas of expertise are Inflammatory Breast Cancer, Breast Cancer, Triple-Negative Breast Cancer, Mastectomy, and Pancreaticoduodenectomy. Dr. Valero is currently accepting new patients.

His clinical research consists of co-authoring 255 peer reviewed articles and participating in 11 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 2 articles in the study of Malnutrition.

Specialties
Thoracic Surgery
General Surgery
Licenses
Surgery in MD
Hospital Affiliations
University Medical Center New Orleans
Touro Infirmary
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Louisiana Healthcare Connections
  • HMO
  • MANAGED MEDICAID PLAN
Managed Medicaid
  • OTHER MANAGED MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 4 Less Insurance Carriers -

Locations

CRESCENT CITY PHYSICIANS INC
2820 Canal St, New Orleans, LA 70119

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

11 Clinical Trials

Inflammatory Breast Cancer (IBC) Registry
Inflammatory Breast Cancer (IBC) Registry
Enrollment Status: Recruiting
Publish Date: October 08, 2024
Intervention Type: Other, Procedure
A Randomized Phase II Study of Neoadjuvant Carboplatin/Paclitaxel (CT) Versus Panitumumab/Carboplatin/Paclitaxel (PaCT) Followed by Anthracycline-Containing Regimen for Newly Diagnosed Primary Triple-Negative Inflammatory Breast Cancer
A Randomized Phase II Study of Neoadjuvant Carboplatin/Paclitaxel (CT) Versus Panitumumab/Carboplatin/Paclitaxel (PaCT) Followed by Anthracycline-Containing Regimen for Newly Diagnosed Primary Triple-Negative Inflammatory Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: October 10, 2025
Intervention Type: Biological, Drug, Other
Study Drugs: Carboplatin, Paclitaxel, Panitumumab
Study Phase: Phase 2
A Phase II Study of Triple Combination of Atezolizumab + Cobimetinib + Eribulin (ACE) or Atezolizumab + Eribulin (AE) in Patients With Recurrent/Metastatic Inflammatory Breast Cancer
A Phase II Study of Triple Combination of Atezolizumab + Cobimetinib + Eribulin (ACE) or Atezolizumab + Eribulin (AE) in Patients With Recurrent/Metastatic Inflammatory Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: September 09, 2025
Intervention Type: Drug, Other
Study Drugs: Atezolizumab, Cobimetinib, Eribulin
Study Phase: Phase 2
A Phase 2 Clinical Trial Assessing the Correlation of Early Changes in Standardized Uptake Value (SUV) on Positron Emission Tomography (PET) With Pathological Complete Response (pCR) to Pertuzumab and Trastuzumab in Patients With Primary Operable HER2-Positive Breast Cancer
A Phase 2 Clinical Trial Assessing the Correlation of Early Changes in Standardized Uptake Value (SUV) on Positron Emission Tomography (PET) With Pathological Complete Response (pCR) to Pertuzumab and Trastuzumab in Patients With Primary Operable HER2-Positive Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: July 01, 2025
Intervention Type: Drug, Procedure
Study Drugs: Trastuzumab, Pertuzumab
Study Phase: Phase 2
A Randomized Phase II Study of Trastuzumab Emtansine (T-DM1) vs. Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT Trial)
A Randomized Phase II Study of Trastuzumab Emtansine (T-DM1) vs. Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT Trial)
Enrollment Status: Active_not_recruiting
Publish Date: March 17, 2025
Intervention Type: Drug
Study Drugs: Trastuzumab, Paclitaxel, Trastuzumab emtansine
Study Phase: Phase 2
A Phase III Multi-center, Randomized, Open-label Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as an Adjuvant Treatment in Patients With Hormone Receptor-positive, HER2-negative Early Breast Cancer (New Adjuvant TriAl With Ribociclib [LEE011]: NATALEE)
A Phase III Multi-center, Randomized, Open-label Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as an Adjuvant Treatment in Patients With Hormone Receptor-positive, HER2-negative Early Breast Cancer (New Adjuvant TriAl With Ribociclib [LEE011]: NATALEE)
Enrollment Status: Active_not_recruiting
Publish Date: November 14, 2024
Intervention Type: Drug, Other
Study Drug: Ribociclib
Study Phase: Phase 3
A Randomized, Double-Blind, Phase III Trial of Taxane/Trastuzumab/Pertuzumab With Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer
A Randomized, Double-Blind, Phase III Trial of Taxane/Trastuzumab/Pertuzumab With Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: September 26, 2024
Intervention Type: Other, Procedure, Biological, Drug
Study Drugs: Atezolizumab, Paclitaxel, Pertuzumab, Trastuzumab
Study Phase: Phase 3
A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel With or Without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer
A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel With or Without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: June 03, 2024
Intervention Type: Drug, Other
Study Drugs: Carboplatin, Cyclophosphamide, Doxorubicin Hydrochloride, Paclitaxel
Study Phase: Phase 3
A Phase Ib Trial of M7824 and Eribulin in Patients With Metastatic Triple Negative Breast Cancer (TNBC)
A Phase Ib Trial of M7824 and Eribulin in Patients With Metastatic Triple Negative Breast Cancer (TNBC)
Enrollment Status: Terminated
Publish Date: October 31, 2022
Intervention Type: Drug
Study Drugs: Bintrafusp Alfa, Eribulin Mesylate
Study Phase: Phase 1
Phase II Study of Denosumab to Define the Role of Bone Related Biomarkers in Breast Cancer Bone Metastasis
Phase II Study of Denosumab to Define the Role of Bone Related Biomarkers in Breast Cancer Bone Metastasis
Enrollment Status: Terminated
Publish Date: November 22, 2019
Intervention Type: Drug
Study Phase: Phase 2
A Phase II Study of BIBF1120 (Nintedanib) for Patients With Metastatic HER2-Negative Inflammatory Breast Cancer (IBC)
A Phase II Study of BIBF1120 (Nintedanib) for Patients With Metastatic HER2-Negative Inflammatory Breast Cancer (IBC)
Enrollment Status: Terminated
Publish Date: July 17, 2019
Intervention Type: Drug, Behavioral
Study Phase: Phase 2
View 10 Less Clinical Trials

255 Total Publications

Adjuvant capecitabine in patients with triple-negative breast cancer after neoadjuvant chemotherapy.
Adjuvant capecitabine in patients with triple-negative breast cancer after neoadjuvant chemotherapy.
Journal: ESMO open
Published: May 21, 2025
Similar Doctors
Advanced in Malnutrition
Dr. Fikre S. Wang
General Surgery
Advanced in Malnutrition
Dr. Fikre S. Wang
General Surgery
3600 Prytania St, Suite 65, 
New Orleans, LA 
 (2.9 miles away)
504-899-4744
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Fikre Wang is a General Surgeon in New Orleans, Louisiana. Dr. Wang is rated as a Distinguished provider by MediFind in the treatment of Malnutrition. His top areas of expertise are Gangrene, Cellulitis, Necrosis, Gastrostomy, and Small Bowel Resection. Dr. Wang is currently accepting new patients.

Experienced in Malnutrition
Dr. John P. Boudreaux
General Surgery
Experienced in Malnutrition
Dr. John P. Boudreaux
General Surgery

Louisiana State University School Of Medicine In New Orleans Faculty G

2832 Burdette St, 
New Orleans, LA 
 (1.6 miles away)
504-866-2741
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

John Boudreaux is a General Surgeon in New Orleans, Louisiana. Dr. Boudreaux is rated as a Distinguished provider by MediFind in the treatment of Malnutrition. His top areas of expertise are Neuroendocrine Tumor, Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET), Pancreatic Islet Cell Tumor, Liver Embolization, and Hernia Surgery. Dr. Boudreaux is currently accepting new patients.

Experienced in Malnutrition
Dr. Ramcharan Thiagarajan
General Surgery
Experienced in Malnutrition
Dr. Ramcharan Thiagarajan
General Surgery

Louisiana State University School Of Medicine In New Orleans Faculty G

2832 Burdette St, 
New Orleans, LA 
 (1.6 miles away)
504-866-2741
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Ramcharan Thiagarajan is a General Surgeon in New Orleans, Louisiana. Dr. Thiagarajan is rated as an Advanced provider by MediFind in the treatment of Malnutrition. His top areas of expertise are Neuroendocrine Tumor, Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET), Gastrointestinal Fistula, Liver Embolization, and Hernia Surgery. Dr. Thiagarajan is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Valero's expertise for a condition
ConditionClose
View All 15 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile